As of June 18, 2025, Avecho Biotechnology Ltd (AVE.AX) reports a Current Ratio of 2.81.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Avecho Biotechnology Ltd's Current Ratio
Over recent years, Avecho Biotechnology Ltd's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2024-12-31 | 2.81 |
| 2023-12-31 | 8.30 |
| 2022-12-31 | 3.82 |
| 2021-12-31 | 6.91 |
| 2020-12-31 | 4.46 |
This slight downward trend highlights how Avecho Biotechnology Ltd manages its short-term assets and liabilities over time.
Comparing Avecho Biotechnology Ltd's Current Ratio to Peers
To better understand Avecho Biotechnology Ltd's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Avecho Biotechnology Ltd (AVE.AX) | 2.81 |
| Auscann Group Holdings Ltd (AC8.AX) | 49.47 |
| Nyrada Inc (NYR.AX) | 25.35 |
| Invion Ltd (IVX.AX) | 18.70 |
| Invex Therapeutics Ltd (IXC.AX) | 14.18 |
| Neurizon Therapeutics Ltd (PAA.AX) | 12.42 |
Compared to its competitors, Avecho Biotechnology Ltd's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.